安慰剂治疗在9种精神疾病中的差异结局:系统综述与荟萃分析
该系统综述与荟萃分析纳入90项高质量安慰剂对照随机临床试验、共9985例安慰剂治疗成人患者,比较9种精神疾病中安慰剂组症状改善的标准化前后效应量。所有疾病安慰剂组症状均改善,但效应量差异显著,重性抑郁障碍(dav=1.40)和广泛性焦虑障碍(dav=1.23)最大,精神分裂症最小(dav=0.59)。
要点
- 9种精神疾病安慰剂组症状均改善,但效应量差异有统计学意义(Q=88.5,P<.001)。
- 重性抑郁障碍(dav=1.40)与广泛性焦虑障碍(dav=1.23)安慰剂效应量最大。
- 强迫症(dav=0.65)与精神分裂症(dav=0.59)安慰剂效应量最小。
核心结论
- 安慰剂治疗在全部9种精神疾病中均带来显著症状改善,但改善幅度因诊断而异。
研究设计与样本
- 系统检索MEDLINE和Cochrane系统综述数据库(2022年3月),选取9种主要精神疾病各前10项最高质量、最新的安慰剂对照随机临床试验,共90项RCT、9985例安慰剂治疗成人患者。
- 由2名作者独立完成研究检索、筛选和数据提取,采用随机效应荟萃分析计算每种诊断的合并前后安慰剂效应量(dav)及95%CI,并用Q检验比较诊断间差异。
主要发现
- 所有诊断安慰剂组症状严重程度均改善,合并前后安慰剂效应量在诊断间存在显著差异(Q=88.5;df=8;P<.001)。
- 重性抑郁障碍(dav=1.40;95%CI,1.24-1.56)和广泛性焦虑障碍(dav=1.23;95%CI,1.06-1.41)的dav最大。
- 惊恐障碍、注意缺陷/多动障碍、创伤后应激障碍、社交恐惧症和躁狂的dav在0.68至0.92之间。
- 强迫症(dav=0.65;95%CI,0.51-0.78)和精神分裂症(dav=0.59;95%CI,0.41-0.76)的dav最小。
关键数值与推荐
- 主要结局为每种诊断的合并前后安慰剂效应量(dav)及95%CI,采用随机效应荟萃分析。
- 诊断间差异用Q检验评估(Q=88.5;df=8;P<.001)。
- 纳入研究为每种诊断前10项最高质量(根据Cochrane偏倚风险工具风险最低)且最新的安慰剂对照RCT,共90项。
临床怎么用
- 这些发现可能有助于评估安慰剂对照的必要性和伦理合理性。
- 这些发现可能有助于在非对照研究中评估治疗效果。
- 这些发现可能有助于指导患者的治疗决策。
局限性
- 这些发现可能涵盖真实安慰剂效应、自然疾病病程和非特异性效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Placebo is the only substance systematically evaluated across common psychiatric diagnoses, but comprehensive cross-diagnostic comparisons are lacking. OBJECTIVE: To compare changes in placebo groups in recent high-quality randomized clinical trials (RCTs) across a broad spectrum of psychiatric disorders in adult patients. DATA SOURCES: MEDLINE and the Cochrane Database of Systematic Reviews were systematically searched in March 2022 for the latest systematic reviews meeting predetermined high-quality criteria for 9 major psychiatric diagnoses. STUDY SELECTION: Using these reviews, the top 10 highest-quality (ie, lowest risk of bias, according to the Cochrane Risk of Bias tool) and most recent placebo-controlled RCTs per diagnosis (totaling 90 RCTs) were selected, adhering to predetermined inclusion and exclusion criteria. DATA EXTRACTION AND SYNTHESIS: Following the Cochrane Handbook, 2 authors independently carried out the study search, selection, and data extraction. Cross-diagnosis comparisons were based on standardized pre-post effect sizes (mean change divided by its SD) for each placebo group. This study is reported following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline. MAIN OUTCOME AND MEASURE: The primary outcome, pooled pre-post placebo effect sizes (dav) with 95% CIs per diagnosis, was determined using random-effects meta-analyses. A Q test assessed statistical significance of differences across diagnoses. Heterogeneity and small-study effects were evaluated as appropriate. RESULTS: A total of 90 RCTs with 9985 placebo-treated participants were included. Symptom severity improved with placebo in all diagnoses. Pooled pre-post placebo effect sizes differed across diagnoses (Q = 88.5; df = 8; P < .001), with major depressive disorder (dav = 1.40; 95% CI, 1.24-1.56) and generalized anxiety disorder (dav = 1.23; 95% CI, 1.06-1.41) exhibiting the largest dav. Panic disorder, attention-deficit/hyperactivity disorder, posttraumatic stress disorder, social phobia, and mania showed dav between 0.68 and 0.92, followed by OCD (dav = 0.65; 95% CI, 0.51-0.78) and schizophrenia (dav = 0.59; 95% CI, 0.41-0.76). CONCLUSION AND RELEVANCE: This systematic review and meta-analysis found that symptom improvement with placebo treatment was substantial in all conditions but varied across the 9 included diagnoses. These findings may help in assessing the necessity and ethical justification of placebo controls, in evaluating treatment effects in uncontrolled studies, and in guiding patients in treatment decisions. These findings likely encompass the true placebo effect, natural disease course, and nonspecific effects.
引用
- Bschor T, Nagel L, Unger J, et al. Differential Outcomes of Placebo Treatment Across 9 Psychiatric Disorders: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024. PMID: 38809560. doi:10.1001/jamapsychiatry.2024.0994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。